Combination of hemoglobin, alkaline phosphatase, and age predicts optimal docetaxel regimen for patients with castration-resistant prostate cancer

• Published in: International journal of clinical oncology 2014-10, Vol.19 (5), p.946-954
• Main Authors: Matsuyama, Hideyasu, Shimabukuro, Tomoyuki, Hara, Isao, Kohjimoto, Yasuo, Suzuki, Kazuhiro, Koike, Hidekazu, Uemura, Hirotsugu, Hayashi, Taiji, Ueno, Munehisa, Kodaira, Kiichiro, Tomita, Yoshihiko, Sakurai, Toshihiko, Shimizu, Nobuaki
• Format: Article
• Language: English
• Subjects: Age Factors; Aged; Aged, 80 and over; Alkaline Phosphatase - blood; Biomarkers, Pharmacological - blood; C-Reactive Protein - metabolism; Cancer Research; Chemotherapy; Hemoglobins - metabolism; Humans; Male; Medical prognosis; Medicine; Medicine & Public Health; Middle Aged; Neoplasm Grading; Oncology; Original Article; Prognosis; Prostate cancer; Prostate-Specific Antigen - blood; Prostatic Neoplasms, Castration-Resistant - blood; Prostatic Neoplasms, Castration-Resistant - drug therapy; Prostatic Neoplasms, Castration-Resistant - pathology; Risk factors; Surgical Oncology; Taxoids - administration & dosage
• ISSN: 1341-9625; 1437-7772
• DOI: 10.1007/s10147-013-0638-2

Background We aimed to find the prognostic factors predicting overall survival (OS) in patients with castration-resistant prostate cancer (CRPC) who had docetaxel (DTX) chemotherapy, and to construct a model predicting the optimum number of cycles of DTX. Methods A total of 279 CRPC patients who received DTX (≥50 mg/m 2 ) every 3–4 weeks were studied retrospectively. Prognostic factors predicting treatment cycles as well as OS were analyzed, and a risk table for predicting treatment cycles was constructed. Results The longer treatment group (>10 cycles) had a significantly longer OS than the standard treatment group ( p  10 cycles, and higher score (7–9) predicting ≤5 cycles ( p